Agenus

AGEN · NASDAQ

$6.42+$0.24 (+3.88%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.18

Latest news

Press releaseOct 9, 3:23 PM ETBusiness Wire
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Press releaseOct 8, 7:30 AM ETBusiness Wire
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Press releaseOct 3, 10:50 AM ETBusiness Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Press releaseOct 2, 9:00 AM ETBusiness Wire
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Press releaseSep 10, 7:30 AM ETBusiness Wire
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Press releaseAug 31, 7:30 AM ETBusiness Wire
Agenus to Participate in Upcoming September Investor Conferences
Press releaseAug 28, 10:07 AM ETBusiness Wire
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Press releaseAug 26, 10:05 AM ETBusiness Wire
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
NewsAug 20, 8:06 AM ETAvi Kapoor
Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Press releaseAug 6, 7:30 AM ETBusiness Wire
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Press releaseJul 28, 4:30 PM ETBusiness Wire
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Press releaseJul 17, 10:28 AM ETBusiness Wire
Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026
NewsJul 14, 11:37 AM ETKaustubh Bagalkote
Why Is Agenus Stock Falling on Tuesday?
NewsJul 14, 8:49 AM ETRishabh Mishra
Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Semiconductor, Twin Vee, JPMorgan In Focus (UPDATED)
NewsJul 13, 9:34 PM ETShivdeep Dhaliwal
Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today
NewsJul 13, 12:48 PM ETAvi Kapoor
Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump
NewsJul 13, 11:29 AM ETVandana Singh
Why Is Agenus Stock Gaining Monday?
NewsJul 13, 10:28 AM ETSurbhi Jain
Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN
NewsJul 13, 9:41 AM ETAvi Kapoor
US Stocks Mixed; Dow Gains Over 100 Points
NewsJul 13, 7:14 AM ET
Market-Moving News for July 13th
Press releaseJul 13, 6:00 AM ETBusiness Wire
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
Press releaseJul 6, 7:30 AM ETBusiness Wire
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Press releaseJun 25, 7:00 AM ETBusiness Wire
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
Press releaseJun 2, 4:30 PM ETBusiness Wire
Agenus Announces Virtual 2026 Annual Shareholders Meeting
Press releaseMay 21, 5:00 PM ETBusiness Wire
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
Press releaseMay 21, 5:00 PM ETBusiness Wire
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
Press releaseMay 15, 4:11 PM ETBusiness Wire
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
Press releaseMay 11, 8:45 AM ETBusiness Wire
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
NewsMay 11, 7:11 AM ET
Earnings Scheduled For May 11, 2026
Press releaseMay 4, 4:30 PM ETBusiness Wire
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
Press releaseApr 21, 10:00 AM ETBusiness Wire
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Press releaseApr 21, 8:00 AM ETBusiness Wire
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
NewsMar 16, 7:11 AM ET
Earnings Scheduled For March 16, 2026
Press releaseDec 12, 10:31 AM ETGlobe Newswire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
NewsNov 10, 7:32 AM ET
Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate
NewsNov 10, 6:12 AM ET
Earnings Scheduled For November 10, 2025
NewsNov 7, 3:05 PM ET
Insights Ahead: Agenus's Quarterly Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026

Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus to Participate in Upcoming September Investor Conferences

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Coty Posts Mixed Q4 Results, Joins Wolfspeed, ATRenew And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026

Why Is Agenus Stock Falling on Tuesday?

Stock Market Today: Dow, S&P 500, Nasdaq 100 Futures Rise on Better-Than-Expected CPI Data—Tower Semiconductor, Twin Vee, JPMorgan In Focus (UPDATED)

Oracle, Twin Vee PowerCats, Agenus, Micron Technology and SanDisk: Why These 5 Stocks Are on Investors' Radars Today

Crude Oil Surges Over 5%; Twin Vee Powercats Shares Jump

Why Is Agenus Stock Gaining Monday?

Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN

US Stocks Mixed; Dow Gains Over 100 Points

Market-Moving News for July 13th

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026

Agenus Announces Virtual 2026 Annual Shareholders Meeting

Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC

Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer

Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development

Earnings Scheduled For May 11, 2026

Agenus to Provide First Quarter 2026 Financial Report and Corporate Update

Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

Earnings Scheduled For March 16, 2026

GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era

Agenus Q3 EPS $1.94 Misses $1.98 Estimate, Sales $30.200M Miss $55.713M Estimate

Earnings Scheduled For November 10, 2025

Insights Ahead: Agenus's Quarterly Earnings